InstalabEMA IgA
Should you take a EMA IgA test?
This test is most useful if any of these apply to you.
About EMA IgA
If you have unexplained digestive symptoms, a family member with celiac disease, type 1 diabetes, or stubbornly low iron or vitamin levels, this is one of the most important tests you can run. EMA IgA (endomysial IgA antibody) detects a very specific autoimmune reaction that almost always means gluten is damaging your small intestine.
What makes this test stand out is its near-perfect specificity. A positive result strongly suggests active celiac disease, often allowing diagnosis without a small bowel biopsy when paired with another celiac antibody at very high levels.
What This Test Actually Measures
EMA IgA is an autoantibody of the IgA class. The lab detects it by placing your blood serum onto thin slices of primate tissue (typically monkey esophagus) and looking under a fluorescent microscope for antibodies that latch onto the connective tissue around smooth muscle fibers, a structure called the endomysium.
The actual molecule your antibodies bind to is an enzyme called tissue transglutaminase 2 (TG2). When you eat gluten and your immune system mistakes it for a threat, B cells (a type of immune cell) produce IgA antibodies against TG2 in the endomysial region. These same antibodies drive the small intestine damage that defines celiac disease.
Why It Matters: Celiac Disease
Celiac disease is an autoimmune reaction to gluten that flattens the finger-like projections (villi) lining your small intestine. Without those villi, your gut cannot absorb nutrients properly, which leads to deficiencies, fatigue, digestive symptoms, and a higher long-term risk of other autoimmune conditions and certain cancers if left untreated.
A positive EMA IgA result is highly specific for active celiac disease with villous atrophy in both adults and children. In one large adult cohort, EMA IgA showed 97.4% sensitivity and 100% specificity, with a positive predictive value of 100%. Translated: when this test is positive in someone with a reasonable suspicion of celiac, the diagnosis is essentially confirmed.
Skin Disease: Dermatitis Herpetiformis
Dermatitis herpetiformis is the skin form of celiac disease. It causes intensely itchy, blistering rashes, usually on the elbows, knees, and buttocks. Most people with this rash test positive for EMA IgA because the same gluten-driven autoimmunity damaging the gut also affects the skin.
Type 1 Diabetes and Other Autoimmune Conditions
If you have type 1 diabetes, your risk of also having celiac disease is significantly elevated. In one study of 391 children with type 1 diabetes, EMA IgA screening found celiac disease in roughly 5% of them, much higher than the general population rate. Many had no obvious gut symptoms.
What this means for you: if you have type 1 diabetes, an autoimmune thyroid condition, or a first-degree relative with celiac disease, EMA IgA testing can catch silent disease that would otherwise go undetected for years.
Kidney Disease Connection
A subset of people with IgA nephropathy (a form of kidney disease where IgA antibodies deposit in the kidneys) test positive for EMA, suggesting a shared gluten-related pathway in some cases. This association is not strong enough to recommend EMA testing for everyone with kidney disease, but it is worth knowing if you have both unexplained kidney findings and gut symptoms.
How EMA IgA Compares to the tTG-IgA Test
The other main celiac antibody test, tTG-IgA (tissue transglutaminase IgA), actually measures antibodies against the same target protein. The difference is the method: tTG-IgA is an automated, quantitative ELISA assay that reports a specific number, while EMA IgA uses subjective visual reading under a microscope and is typically reported as positive or negative with a titer (dilution level).
In most current guidelines, tTG-IgA is the first-line screening test because it is cheaper, automated, and slightly more sensitive. EMA IgA is then used as a confirmatory test, especially when tTG-IgA is at least 10 times the upper limit of normal. This combination forms the basis of the so-called no-biopsy diagnostic pathway.
| Test Setting | EMA IgA Performance | tTG-IgA Performance |
|---|---|---|
| Untreated celiac disease (on gluten) | Sensitivity around 88 to 98%, specificity around 97 to 100% | Sensitivity around 90 to 98%, specificity around 87 to 99% |
| Pediatric biopsy-confirmed cohort | Sensitivity 77.5%, specificity 97.3% | Sensitivity 87.5%, specificity 95.4% |
| Monitoring villous damage on gluten-free diet | Sensitivity around 45%, specificity around 91% | Sensitivity around 50%, specificity around 83% |
Source: Hill 2005, Rostom 2005, Pacheco 2024, Silvester 2017, Maimaris 2025.
What this means for you: a positive EMA IgA result is one of the strongest signals you can get for active celiac disease. But a negative result on a gluten-free diet does not guarantee your intestine has fully healed.
The No-Biopsy Diagnostic Pathway
For decades, confirming celiac disease required an upper endoscopy with small bowel biopsy. Now, guidelines from the European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) allow diagnosis without biopsy in specific situations: a tTG-IgA level at or above 10 times the upper limit of normal, plus a positive EMA IgA on a second blood sample.
In a study of 933 children meeting these criteria, all had positive EMA IgA, most with very high titers between 1:20 and 1:160. In adults, a similar approach works when tTG-IgA is very high and EMA is positive at a dilution of 1:160 or above. The combined positive predictive value of this pattern approaches 100% for celiac disease.
Reference Ranges and Result Interpretation
EMA IgA is reported as positive or negative, often along with a titer that tells you how many times your serum was diluted before the antibody signal disappeared. Reference ranges below come from published research; your lab may use slightly different cutoffs or reporting formats.
| Result | What It Suggests |
|---|---|
| Negative | No detectable endomysial antibodies. Active celiac disease is unlikely if you are still eating gluten, but does not rule out other gut conditions or healing on a gluten-free diet. |
| Positive at low titer (e.g., 1:5 to 1:10) | Suggests celiac autoimmunity. Confirmation with quantitative tTG-IgA and likely biopsy is warranted. |
| Positive at high titer (e.g., 1:80 to 1:160 or higher) | Strongly suggests active celiac disease with villous damage. In combination with very high tTG-IgA, may support diagnosis without biopsy. |
Source: Pacheco 2024, Ben-Tov 2024, Wakim-Fleming 2013. Compare your results within the same lab over time. Different labs use different substrates, reading techniques, and dilution protocols, so a 1:40 at one lab may not match a 1:40 at another.
When Results Can Be Misleading
A handful of factors can distort your EMA IgA result. Understanding them helps you interpret your number correctly.
- Gluten-free diet before testing: if you have already cut gluten from your diet, your antibodies fall and may turn negative within weeks to months, even if you genuinely have celiac disease. To get accurate results, you generally need to be eating gluten regularly for several weeks before the test.
- IgA deficiency: roughly 1 in 500 people make very little IgA. Since EMA IgA depends on IgA antibodies, a deficient person can have celiac disease but test negative. This is why your doctor should order a total IgA level alongside celiac serology.
- Reader variability: EMA testing requires a trained technician to visually interpret immunofluorescence patterns. Different labs and different readers can disagree, especially at low titers. Results near the detection threshold are more uncertain than strongly positive ones.
- Treated celiac disease on a gluten-free diet: EMA usually becomes negative when you stop eating gluten, but this does not always mean your intestine has healed. Roughly half of people on a gluten-free diet with negative EMA still have ongoing villous damage on biopsy.
Tracking Your Trend
A single EMA IgA result tells you whether you currently have detectable celiac autoimmunity. Tracking over time tells you something different and equally useful: whether your gluten-free diet is working.
After a positive diagnosis and starting a strict gluten-free diet, EMA titers typically fall over months and often turn negative. Persistent positivity usually signals ongoing gluten exposure, intentional or hidden. Once negative, EMA generally stays negative as long as you avoid gluten.
A reasonable cadence: get a baseline at diagnosis, retest at 6 and 12 months after starting a gluten-free diet, and then annually. Be aware that a negative EMA on diet is reassuring but not proof of healing. If you are still having symptoms or your nutrient absorption has not improved, a follow-up endoscopy may be needed even with negative antibodies.
What to Do If Your Result Is Abnormal
A positive EMA IgA result is rarely a false alarm. Here is the decision pathway:
- Confirm with a quantitative tTG-IgA test if you have not already. Together, the two antibodies build a strong case.
- Get a total IgA level to make sure you are not missing IgA deficiency.
- See a gastroenterologist familiar with celiac disease. Depending on your tTG-IgA level and clinical picture, you may either qualify for a no-biopsy diagnosis or need an upper endoscopy with small bowel biopsy to confirm villous atrophy.
- Do not start a gluten-free diet until testing is complete. Going gluten-free before biopsy can normalize the intestine just enough to make diagnosis difficult.
- Screen for nutrient deficiencies common in untreated celiac disease, including iron, vitamin D, vitamin B12, folate, and calcium.
- Consider screening first-degree relatives. Celiac disease runs in families, and many affected relatives have no symptoms.
What Moves This Biomarker
Evidence-backed interventions that affect your EMA IgA level